Quantcast

Latest ViroPharma Incorporated Stories

2011-07-28 06:30:00

EXTON, Pa., July 28, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the second quarter ended June 30, 2011. In the second quarter of 2011, we: Achieved a record $129 million in net product sales, including $62.5 million in net sales of Cinryze® (C1 esterase inhibitor [human]) representing Cinryze growth of 55 percent over the same period in 2010;Realized non-GAAP adjusted net income of $36 million; GAAP net income reached $23...

2011-07-21 15:00:00

EXTON, Pa., July 21, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2011 are expected to be released on Thursday, July 28, 2011 before the open of the U.S.

2011-06-24 05:10:00

EXTON, Pa., June 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.

2011-06-15 09:30:00

EXTON, Pa., June 15, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted ViroPharma Centralized Marketing Authorization for Cinryze® (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

2011-06-13 07:00:00

ISTANBUL, June 13, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that data relating to Cinryze® (C1 esterase inhibitor [human]) from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.

2011-06-02 15:00:00

EXTON, Pa., June 2, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Jefferies 2011 Global Healthcare Conference at 2:00 P.M. ET on Wednesday, June 8, 2011.

2011-05-26 10:03:00

EXTON, Pa., May 26, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the launch of the documentary Swell, a twenty-five minute film that allows families dealing with the rare genetic swelling disease, hereditary angioedema (HAE), to share the challenges and triumphs of living with a chronic disorder.

2011-05-19 08:57:00

EXTON, Pa., May 19, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI. The objectives of this randomized, double-blind, placebo-controlled, dose ranging study are to evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days in...


Word of the Day
tourtiere
  • a meat pie that is usually eaten at Christmas in Quebec
The word 'tourtiere' comes from the French tourte, or passenger pigeon.
Related